8-K: 4D Molecular Therapeutics Holds 2024 Annual Meeting, Elects Director and Ratifies Auditor

4D Molecular Therapeutics held its 2024 Annual Meeting, electing David Kirn, M.D. as a Class I director and ratifying PricewaterhouseCoopers LLP as its independent auditor for the fiscal year ending December 31, 2024.

Summary

• 4D Molecular Therapeutics held its 2024 Annual Meeting of Stockholders virtually on May 21, 2024.
• There were 51,157,472 shares of common stock outstanding as of the record date, April 3, 2024.
• A total of 45,054,713 shares were voted at the meeting.
• The stockholders elected David Kirn, M.D. as a Class I director to serve until the 2027 Annual Meeting.
• PricewaterhouseCoopers LLP was ratified as the company's independent auditor for the fiscal year ending December 31, 2024.

Sentiment

Score: 7

Explanation: The document reflects standard corporate governance procedures, indicating a stable and routine operational environment. There are no indications of any issues or concerns.

Positives

• The election of the director and ratification of the auditor were both approved by a significant majority of votes.
• The company successfully held its annual meeting and completed the necessary voting procedures.

Industry Context

This announcement is a routine corporate governance activity for a publicly traded company, ensuring compliance with regulatory requirements and shareholder engagement.

Comparison to Industry Standards

• The election of directors and ratification of auditors are standard practices for publicly traded companies like 4D Molecular Therapeutics.
• The voting results are typical for such meetings, with the majority of shares voting in favor of the proposals.
• Companies like BioMarin Pharmaceutical and Sarepta Therapeutics also hold similar annual meetings to elect directors and ratify auditors.

Management Changes

Stakeholder Impact

• Shareholders have exercised their voting rights to elect a director and ratify the auditor.
• The company has fulfilled its corporate governance obligations.

Key Dates

Keywords

Annual Meeting, Director Election, Auditor Ratification, Stockholders, Corporate Governance, PricewaterhouseCoopers, David Kirn